About Centenial Surgical Suture
Centenial Surgical Suture is a publicly listed company based in Thane (India) founded in 2002. Atraumatic surgical sutures and medical devices are manufactured. The company has 280 employees. Its Indian entity Centenial Surgical Suture Limited reported revenue of ₹54.01 Cr. Centenial Surgical Suture offers products and services including Absorbable Sutures and Non-Absorbable Sutures. Its focus areas include Traditional Medical Devices.
Company details
Centenial Surgical Suture was founded in 2002 in Thane, India, within the medical devices sector. Absorbable and non-absorbable sutures are produced, along with customized suture-needle combinations tailored to surgical requirements. Operations adhere to international standards such as ISO 13485:2016, ISO 9001:2015, ISO 45001:2018, WHO GMP, and CE marking. Inquiries are monitored from initial contact through to product delivery, with manufacturing conducted using advanced equipment under rigorous quality controls.
- Headquarters Thane, India
- Employees 280
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website centenialindia.com
- Social LinkedIn Facebook
- Legal Name Centenial Surgical Suture Ltd.
- Market Cap₹27.40 Cr
CSURGSU · BSE
- Share Price₹78.86
+4.99% today
- Revenue₹53.84 Cr
FY 2025-26 · +0.6% YoY
- EBITDA₹5.25 Cr
Margin 9.8%
- Net Profit−₹2.22 Cr
FY 2025-26 · -54.2% YoY
- ROE-7.4%
ROCE 2.3%
- Debt / Equity0.97
Interest cover 280.8x
- Employee Count280
Associated legal entities of Centenial Surgical Suture
Centenial Surgical Suture operates through Centenial Surgical Suture Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Centenial Surgical Suture Limited Listed CIN L99999MH1995PLC089759 | Active | 20 Jun 1995 | Thane, Maharashtra | ₹54.0 Cr | 238 | 10 | View details |
Products & Services of Centenial Surgical Suture
Centenial Surgical Suture offers a comprehensive portfolio of products and services, including Absorbable Sutures and Non-Absorbable Sutures.
Absorbable sutures are produced for surgical applications where materials dissolve over time in the body.
Non-absorbable sutures are manufactured for long-term surgical needs where permanence is required.
Board of directors of Centenial Surgical Suture Limited (Centenial Surgical Suture)
Centenial Surgical Suture Limited is the primary company behind Centenial Surgical Suture. The board of Centenial Surgical Suture Limited currently have 7 directors; the longest-serving is Vijay Kalidas Majrekar, appointed in 1995. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vijay Kalidas Majrekar DIN 00804808 | Managing Director | 20 Jun 1995 | 31 yrs 4 mo | Centenial Surgical Suture Limited |
| Devraj Poojary DIN 02041726 | Whole-time director | 01 Feb 2011 | 15 yrs 9 mo | Centenial Surgical Suture Limited |
| Anuradha Raghunandan Kashikar DIN 00804831 | Whole-time director | 28 Sep 2015 | 11 yrs 1 mo | Centenial Surgical Suture Limited |
| Neel Mukesh Vora DIN 07699873 | Director | 09 Jan 2017 | 9 yrs 10 mo | Centenial Surgical Suture Limited |
| Akash Sunil Modi DIN 08698016 | Director | 01 Apr 2024 | 2 yrs 7 mo | Centenial Surgical Suture Limited |
| Ridhima Bhushan Limaye DIN 10256393 | Director | 01 Apr 2024 | 2 yrs 7 mo | Centenial Surgical Suture Limited |
| Anuj Vipulbhai Shah DIN 10256390 | Director | 01 Apr 2024 | 2 yrs 7 mo | Centenial Surgical Suture Limited |
People of Centenial Surgical Suture
1 people are tracked at Centenial Surgical Suture (1 in leadership); the tracked headcount is 280.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for Centenial Surgical Suture
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Centenial Surgical Suture
Centenial Surgical Suture is a publicly listed company on the BSE with ticker symbol CSURGSU in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Dec 2007
- Listed onBSE: 531380
- Listed entityCentenial Surgical Suture Ltd.
- Exchange sectorHealth technology
- ISININE405H01018
- Share price₹74.90 (-4.34% on the day) · 2026-10-14
- Market capitalisation₹28.6 Cr
- EPS (diluted, trailing year)₹-3.96
- Volume (last session)1,176
Financials of Centenial Surgical Suture
Exchange-reported figures of Centenial Surgical Suture Limited, the listed company behind Centenial Surgical Suture (BSE: CSURGSU).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 53.84 | 53.52 | 51.19 | 52.66 | 44.43 | 36.93 | 55.61 |
| Revenue growth | +0.6% | +4.6% | -2.8% | +18.5% | +20.3% | -33.6% | - |
| EBITDA | 5.25 | 6.44 | 5.16 | 4.40 | 4.48 | 5.11 | 5.92 |
| EBITDA margin | +9.8% | +12.0% | +10.1% | +8.4% | +10.1% | +13.8% | +10.7% |
| Profit before tax | (2.09) | (1.59) | 1.28 | 1.46 | 1.06 | 1.53 | 2.15 |
| Net profit | (2.22) | (1.44) | 1.14 | 0.88 | 0.61 | 0.96 | 1.29 |
| Net profit margin | -4.1% | -2.7% | +2.2% | +1.7% | +1.4% | +2.6% | +2.3% |
| EPS (₹) | (4.06) | (2.70) | 2.09 | 1.63 | 1.16 | 1.77 | 2.39 |
| Balance sheet | |||||||
| Total assets | 58.93 | 65.01 | 60.62 | 47.01 | 46.22 | 50.64 | 49.70 |
| Net worth | 28.55 | 30.75 | 32.21 | 31.08 | 30.19 | 29.57 | 28.60 |
| Total debt | 27.31 | 30.01 | 23.24 | 9.92 | 9.30 | 13.47 | 12.72 |
| Cash & bank | 0.20 | 0.22 | 0.68 | 0.33 | 0.26 | 0.54 | 0.72 |
| Net working capital | 39.17 | 43.39 | 46.90 | 40.20 | 38.37 | 41.38 | 38.50 |
| Cash flow | |||||||
| Cash from operations | 7.28 | 17.07 | 6.21 | 1.30 | 4.75 | 1.97 | 2.08 |
| Cash from investing | (2.41) | (11.61) | (7.92) | (0.18) | (0.17) | (0.89) | (1.31) |
| Cash from financing | (4.89) | (5.93) | 2.06 | (1.05) | (4.87) | (1.27) | (0.37) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.34 | 12.58 | 14.86 | 13.46 | 12.94 | 13.31 | 12.20 | 14.27 |
| Revenue growth (YoY) | +18.6% | -5.5% | +21.8% | -5.7% | -5.8% | - | - | - |
| Other income | 0.01 | 0.07 | 0.05 | 0.05 | 0.00 | 0.05 | 0.01 | 0.06 |
| Total expenses | 13.16 | 11.65 | 13.33 | 12.06 | 11.71 | 11.24 | 11.45 | 12.55 |
| EBITDA | 2.18 | 0.93 | 1.53 | 1.40 | 1.23 | 2.07 | 0.75 | 1.72 |
| EBITDA margin | +14.2% | +7.4% | +10.3% | +10.4% | +9.5% | +15.6% | +6.1% | +12.1% |
| Depreciation | 0.92 | 1.02 | 1.04 | 0.99 | 0.95 | 1.26 | 1.11 | 1.09 |
| Interest | 0.29 | 2.21 | 0.35 | 0.46 | 0.32 | 2.19 | 0.50 | 0.53 |
| Profit before tax | 0.98 | (2.23) | 0.19 | 0.00 | (0.04) | (1.33) | (0.85) | 0.16 |
| Tax | 0.25 | 0.09 | 0.05 | 0.00 | 0.00 | (0.15) | 0.00 | 0.04 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.34 | 12.58 | 14.86 | 13.46 | 12.94 | 13.31 | 12.20 | 14.27 |
| Revenue growth (YoY) | +18.6% | -5.5% | +21.8% | -5.7% | -5.8% | - | - | - |
| Other income | 0.01 | 0.07 | 0.05 | 0.05 | 0.00 | 0.05 | 0.01 | 0.06 |
| Total expenses | 13.16 | 11.65 | 13.33 | 12.06 | 11.71 | 11.24 | 11.45 | 12.55 |
| EBITDA | 2.18 | 0.93 | 1.53 | 1.40 | 1.23 | 2.07 | 0.75 | 1.72 |
| EBITDA margin | +14.2% | +7.4% | +10.3% | +10.4% | +9.5% | +15.6% | +6.1% | +12.1% |
| Depreciation | 0.92 | 1.02 | 1.04 | 0.99 | 0.95 | 1.26 | 1.11 | 1.09 |
| Interest | 0.29 | 2.21 | 0.35 | 0.46 | 0.32 | 2.19 | 0.50 | 0.53 |
| Profit before tax | 0.98 | (2.23) | 0.19 | 0.00 | (0.04) | (1.33) | (0.85) | 0.16 |
| Tax | 0.25 | 0.09 | 0.05 | 0.00 | 0.00 | (0.15) | 0.00 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 53.84 | 53.52 | 51.19 | 52.66 | 44.43 | 36.93 | 55.61 |
| Revenue growth | +0.6% | +4.6% | -2.8% | +18.5% | +20.3% | -33.6% | - |
| Other income | 0.17 | 0.12 | 0.13 | 0.13 | 0.04 | 0.09 | 0.09 |
| Total expenses | 48.59 | 47.08 | 46.03 | 48.26 | 39.95 | 31.82 | 49.69 |
| Employee cost | 11.75 | 11.86 | 11.33 | 11.19 | 10.77 | 9.98 | 10.67 |
| EBITDA | 5.25 | 6.44 | 5.16 | 4.40 | 4.48 | 5.11 | 5.92 |
| EBITDA margin | +9.8% | +12.0% | +10.1% | +8.4% | +10.1% | +13.8% | +10.7% |
| Depreciation | 4.00 | 4.25 | 1.39 | 1.30 | 1.53 | 1.55 | 1.55 |
| Interest | 3.51 | 3.90 | 2.62 | 1.77 | 1.93 | 2.12 | 2.31 |
| Profit before tax | (2.09) | (1.59) | 1.28 | 1.46 | 1.06 | 1.53 | 2.15 |
| Tax | 0.13 | (0.15) | 0.14 | 0.58 | 0.45 | 0.57 | 0.86 |
| Net profit | (2.22) | (1.44) | 1.14 | 0.88 | 0.61 | 0.96 | 1.29 |
| Net profit margin | -4.1% | -2.7% | +2.2% | +1.7% | +1.4% | +2.6% | +2.3% |
| EPS (₹) | (4.06) | (2.70) | 2.09 | 1.63 | 1.16 | 1.77 | 2.39 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
| Reserves & surplus | 23.13 | 25.33 | 26.79 | 25.66 | 24.77 | 24.15 | 23.18 |
| Shareholders' funds (net worth) | 28.55 | 30.75 | 32.21 | 31.08 | 30.19 | 29.57 | 28.60 |
| Secured loans | 10.71 | 12.26 | 14.44 | 9.92 | 9.30 | 12.27 | 11.52 |
| Unsecured loans | 16.60 | 17.75 | 8.80 | 0.00 | 0.00 | 1.20 | 1.20 |
| Total debt | 27.31 | 30.01 | 23.24 | 9.92 | 9.30 | 13.47 | 12.72 |
| Total liabilities | 58.93 | 65.01 | 60.62 | 47.01 | 46.22 | 50.64 | 49.70 |
| Assets | |||||||
| Gross block | 45.17 | 42.94 | 31.47 | 23.78 | 23.62 | 23.46 | 23.38 |
| Net block | 18.22 | 19.98 | 12.77 | 6.47 | 7.61 | 8.97 | 10.44 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 40.65 | 43.48 | 42.52 | 37.24 | 32.26 | 36.23 | 32.20 |
| Sundry debtors | 18.28 | 18.40 | 18.80 | 20.59 | 19.53 | 22.40 | 23.35 |
| Cash & bank balances | 0.20 | 0.22 | 0.68 | 0.33 | 0.26 | 0.54 | 0.72 |
| Loans & advances | 0.90 | 0.87 | 3.31 | 1.20 | 1.22 | 1.44 | 1.67 |
| Total current assets | 60.03 | 62.97 | 65.31 | 59.36 | 53.27 | 60.61 | 57.94 |
| Total current liabilities | 20.86 | 19.58 | 18.41 | 19.16 | 14.90 | 19.23 | 19.44 |
| Net working capital | 39.17 | 43.39 | 46.90 | 40.20 | 38.37 | 41.38 | 38.50 |
| Total assets | 58.93 | 65.01 | 60.62 | 47.01 | 46.22 | 50.64 | 49.70 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.22 | 0.68 | 0.33 | 0.26 | 0.54 | 0.72 | 0.33 |
| Net cash from operating activities | 7.28 | 17.07 | 6.21 | 1.30 | 4.75 | 1.97 | 2.08 |
| Net cash from investing activities | (2.41) | (11.61) | (7.92) | (0.18) | (0.17) | (0.89) | (1.31) |
| Net cash from financing activities | (4.89) | (5.93) | 2.06 | (1.05) | (4.87) | (1.27) | (0.37) |
| Net change in cash | (0.02) | (0.47) | 0.35 | 0.07 | (0.28) | (0.18) | 0.40 |
| Closing cash | 0.20 | 0.22 | 0.68 | 0.33 | 0.26 | 0.54 | 0.72 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +0.6% | +4.6% | -2.8% | +18.5% | +20.3% | -33.6% | - |
| EBITDA growth | -18.5% | +24.8% | +17.3% | -1.8% | -12.3% | -13.7% | - |
| PBT growth | -31.5% | - | -12.3% | +37.7% | -30.7% | -28.8% | -24.0% |
| Net income growth | -54.2% | -226.3% | +29.6% | +44.3% | -36.5% | -25.6% | - |
| Revenue CAGR (3Y) | +0.7% | +6.4% | +11.5% | -1.8% | -7.5% | -11.2% | +1.7% |
| EBITDA CAGR (3Y) | +6.1% | +12.9% | +0.3% | -9.4% | -6.0% | +4.5% | +6.7% |
| Profitability & leverage | |||||||
| Net income margin | -4.1% | -2.7% | +2.2% | +1.7% | +1.4% | +2.6% | +2.3% |
| Return on capital employed | +2.3% | +3.7% | +7.2% | +7.0% | +6.2% | +7.3% | +9.7% |
| Return on net worth | -7.4% | -4.6% | +3.6% | +2.9% | +2.1% | +3.3% | +4.6% |
| Debt / equity | 0.97 | 0.85 | 0.52 | 0.31 | 0.38 | 0.45 | 0.46 |
| Long-term debt / equity | 0.58 | 0.42 | 0.14 | 0.00 | 0.02 | 0.04 | 0.04 |
| Interest cover | 280.80 | 178.08 | 69.50 | 57.10 | 65.42 | 59.55 | 52.86 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.22 | 1.44 | 1.85 | 2.22 | 1.89 | 1.58 | 2.86 |
| Inventory turnover | 1.28 | 1.24 | 1.28 | 1.52 | 1.30 | 1.08 | 1.79 |
| Debtors turnover | 2.94 | 2.88 | 2.60 | 2.63 | 2.12 | 1.61 | 2.52 |
| EPS (₹) | (4.06) | (2.70) | 2.09 | 1.63 | 1.16 | 1.77 | 2.39 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 52.63 | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 | 52.74 |
Top companies in Traditional Diagnostics & Medical Devices
2 companies that operate in the same segment as Centenial Surgical Suture (Traditional Diagnostics & Medical Devices) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical surgical consumables including sutures and anti-microbial gloves are manufactured. | 1992 | Bengaluru, Karnataka, India | USD 7.14 K | 39 | ||
Manufacturer of medical equipments | 1967 | Bengaluru, Karnataka, India | USD 58.9 M | USD 62.39 M | 664 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Centenial Surgical Suture
Complete news archive for Centenial Surgical Suture
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Centenial Surgical Suture
Centenial Surgical Suture was founded in 2002.
Centenial Surgical Suture is headquartered in Thane, India. It is registered at Thane, Maharashtra, India.
Centenial Surgical Suture has 280 employees.
The primary company behind Centenial Surgical Suture, Centenial Surgical Suture Limited, reported revenue of ₹54.01 Cr for FY 2026, up 1% year on year.
Centenial Surgical Suture was founded in 2002 in Thane, India, within the medical devices sector. Absorbable and non-absorbable sutures are produced, along with customized suture-needle combinations tailored to surgical requirements. Operations adhere to international standards such as ISO 13485:2016, ISO 9001:2015, ISO 45001:2018, WHO GMP, and CE marking. Inquiries are monitored from initial contact through to product delivery, with manufacturing conducted using advanced equipment under rigorous quality controls.
Centenial Surgical Suture offers Absorbable Sutures and Non-Absorbable Sutures.
Yes, Centenial Surgical Suture is publicly traded on BSE under the ticker symbol CSURGSU.
Centenial Surgical Suture operates through Centenial Surgical Suture Limited.
The legal entities of Centenial Surgical Suture currently have 8 directors, including Anuradha Raghunandan Kashikar, Devraj Poojary, Vijay Kalidas Majrekar and others.